Kyv-101
Secondary Progressive Multiple Sclerosis
Explore 35 assets in Secondary Progressive Multiple Sclerosis →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Kyverna Therapeutics
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06384976CT.gov KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | — | Active Not Recruiting | — | — | — |
NCT06138132CT.gov A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Secondary Progressive Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Kyv-101 (this asset) | Kyverna Therapeutics | P2 | B · 60 |
| Siponimod | Novartis Pharmaceuticals | P4 | BBB |
| Fampridine | University College Dublin | P4 | BBB |
| Rituximab | Cairo University | P3 | BB |
| bnt162 | Novartis Pharmaceuticals | P4 | BB |
| mis416 | Innate Immunotherapeutics | P2 | BB |
| Simvastatin | University College, London | P3 | BB |
| Natalizumab | Biogen | P3 | BB |
| Remibrutinib | Moein Amin | P3 | BB |
+42 more in the Secondary Progressive Multiple Sclerosis cohort
Other indications for Kyv-101
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Progressive Multiple Sclerosis | — | P2 | B · 60 |
| Multiple Sclerosis | — | P2 | CCC · 52 |
| Chronic Progressive Multiple Sclerosis | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Kyv-101 in Secondary Progressive Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/kyv-101-secondary-progressive-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →